Your browser is no longer supported. Please, upgrade your browser.
Settings
CDAK [NASD]
Codiak BioSciences, Inc.
Index- P/E- EPS (ttm)- Insider Own6.79% Shs Outstand20.33M Perf Week3.65%
Market Cap375.41M Forward P/E- EPS next Y-4.21 Insider Trans0.78% Shs Float14.09M Perf Month-6.64%
Income- PEG- EPS next Q-1.05 Inst Own77.00% Short Float8.33% Perf Quarter-12.63%
Sales15.97M P/S23.50 EPS this Y-31.50% Inst Trans0.16% Short Ratio9.26 Perf Half Y-27.55%
Book/sh3.38 P/B5.12 EPS next Y-9.90% ROA- Target Price- Perf Year-
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range7.90 - 37.85 Perf YTD-46.44%
Dividend- P/FCF- EPS past 5Y- ROI-229.60% 52W High-54.29% Beta-
Dividend %- Quick Ratio8.70 Sales past 5Y- Gross Margin- 52W Low118.99% ATR1.14
Employees105 Current Ratio8.70 Sales Q/Q9744.00% Oper. Margin- RSI (14)45.17 Volatility7.26% 6.29%
OptionableNo Debt/Eq0.37 EPS Q/Q36.60% Profit Margin- Rel Volume0.72 Prev Close17.78
ShortableYes LT Debt/Eq0.37 Earnings- Payout- Avg Volume126.72K Price17.30
Recom1.50 SMA200.71% SMA50-14.81% SMA200-4.57% Volume91,358 Change-2.70%
Nov-09-20Initiated Wedbush Outperform $19
Nov-09-20Initiated Goldman Buy $29
Jul-08-21 02:30AM  
Jul-07-21 08:30AM  
Jul-06-21 04:30PM  
Jun-15-21 08:00AM  
Jun-02-21 08:30AM  
May-25-21 06:00AM  
May-20-21 04:05PM  
May-19-21 09:01AM  
May-11-21 08:00AM  
May-10-21 08:00AM  
May-06-21 04:01PM  
Apr-27-21 04:30PM  
11:10AM  
Apr-22-21 07:00AM  
Apr-10-21 08:30AM  
Mar-30-21 09:30AM  
Mar-17-21 07:30AM  
Mar-10-21 04:38PM  
Feb-20-21 01:27AM  
Feb-17-21 04:30PM  
Feb-11-21 10:18PM  
Feb-09-21 04:17PM  
Feb-04-21 07:30AM  
Jan-21-21 09:00AM  
Jan-13-21 11:58PM  
Dec-30-20 07:00AM  
Dec-21-20 09:00AM  
Nov-27-20 11:55AM  
Nov-23-20 07:30AM  
Nov-19-20 04:05PM  
Nov-09-20 08:00AM  
Oct-23-20 06:00PM  
Oct-13-20 07:04PM  
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12, an exosome therapeutic candidates, for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; exoASO-NLRP3 for multiple sclerosis, neuropathy, and neurodegeneration; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics, Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Morrison BriggsDirectorFeb 17Buy21.004,76199,9814,761Feb 17 06:05 PM
MELAS KYRIAZI THEODirectorOct 13Buy15.006,60099,0006,600Apr 30 04:05 PM
VIR Vir Biotechnology, Inc. daily Stock Chart
VIR [NASD]
Vir Biotechnology, Inc.
Index- P/E- EPS (ttm)-3.10 Insider Own5.30% Shs Outstand127.74M Perf Week-3.36%
Market Cap4.69B Forward P/E- EPS next Y-1.08 Insider Trans-2.85% Shs Float112.96M Perf Month-24.60%
Income-390.30M PEG- EPS next Q-0.48 Inst Own88.10% Short Float7.63% Perf Quarter-25.32%
Sales72.60M P/S64.65 EPS this Y56.50% Inst Trans7.13% Short Ratio12.02 Perf Half Y-44.76%
Book/sh5.10 P/B6.99 EPS next Y54.40% ROA-42.50% Target Price- Perf Year-24.25%
Cash/sh5.57 P/C6.40 EPS next 5Y7.00% ROE-56.90% 52W Range25.31 - 141.01 Perf YTD33.12%
Dividend- P/FCF- EPS past 5Y- ROI-41.40% 52W High-74.72% Beta-
Dividend %- Quick Ratio2.80 Sales past 5Y- Gross Margin- 52W Low40.85% ATR1.95
Employees340 Current Ratio2.80 Sales Q/Q-64.90% Oper. Margin- RSI (14)35.77 Volatility4.22% 5.00%
OptionableYes Debt/Eq0.00 EPS Q/Q-85.50% Profit Margin- Rel Volume0.72 Prev Close36.39
ShortableYes LT Debt/Eq0.00 EarningsAug 05 AMC Payout- Avg Volume716.42K Price35.65
Recom2.20 SMA20-6.19% SMA50-16.16% SMA200-17.81% Volume517,200 Change-2.03%
Jun-04-21Resumed Robert W. Baird Neutral $45
Jan-27-21Downgrade JP Morgan Neutral → Underweight $30
Jan-20-21Reiterated H.C. Wainwright Buy $100 → $125
Oct-05-20Initiated BofA Securities Buy $55
Sep-14-20Upgrade Goldman Neutral → Buy $48 → $54
Sep-11-20Upgrade JP Morgan Underweight → Neutral $29
Aug-20-20Initiated Needham Buy $62
Mar-19-20Downgrade JP Morgan Neutral → Underweight $26
Mar-13-20Downgrade Goldman Buy → Neutral
Feb-27-20Downgrade Robert W. Baird Neutral → Underperform $17
Feb-04-20Downgrade JP Morgan Overweight → Neutral $25 → $26
Nov-14-19Initiated Robert W. Baird Neutral
Nov-05-19Initiated JP Morgan Overweight $25
Nov-05-19Initiated Goldman Buy $37
Nov-05-19Initiated Cowen Outperform
Nov-05-19Initiated Barclays Overweight $25
Jul-29-21 03:05PM  
Jul-28-21 01:08PM  
08:51AM  
07:09AM  
06:20AM  
Jul-22-21 04:05PM  
Jul-21-21 08:06AM  
Jul-16-21 10:59AM  
Jul-15-21 09:46AM  
09:41AM  
08:30AM  
Jun-25-21 07:17PM  
03:02PM  
08:50AM  
Jun-21-21 12:53PM  
11:41AM  
07:29AM  
07:06AM  
Jun-14-21 08:00AM  
Jun-02-21 04:05PM  
May-28-21 05:21PM  
10:44AM  
May-27-21 08:10AM  
07:44AM  
06:29AM  
May-26-21 06:57PM  
05:55PM  
May-24-21 12:27PM  
May-21-21 11:56AM  
09:26AM  
08:04AM  
02:19AM  
May-19-21 06:44AM  
May-10-21 04:05PM  
May-07-21 05:53AM  
May-06-21 07:35PM  
04:05PM  
Apr-29-21 05:04PM  
Apr-22-21 04:01PM  
Apr-21-21 08:50AM  
08:00AM  
08:00AM  
06:52AM  
Apr-17-21 06:00AM  
Apr-16-21 07:14AM  
Apr-15-21 09:51AM  
08:59AM  
Apr-08-21 08:30AM  
Apr-06-21 04:01PM  
Apr-05-21 09:08AM  
08:00AM  
Mar-31-21 01:33PM  
Mar-29-21 08:44AM  
08:30AM  
08:30AM  
Mar-26-21 12:42PM  
08:40AM  
08:30AM  
Mar-25-21 10:55PM  
Mar-24-21 01:03AM  
Mar-21-21 10:29PM  
Mar-18-21 05:13PM  
Mar-16-21 10:33PM  
02:09PM  
07:35AM  
Mar-14-21 09:21PM  
06:35AM  
Mar-12-21 09:33AM  
08:04AM  
06:20AM  
Mar-11-21 05:12PM  
04:18PM  
08:38AM  
08:19AM  
06:45AM  
05:13AM  
Mar-10-21 08:22PM  
12:05AM  
Mar-07-21 08:55PM  
Mar-05-21 09:04AM  
07:54AM  
Mar-04-21 02:47PM  
12:52PM  
10:27AM  
08:35AM  
08:29AM  
Mar-03-21 04:35PM  
02:57PM  
12:55PM  
09:00AM  
Feb-25-21 04:01PM  
Feb-17-21 02:20PM  
01:00PM  
09:29AM  
08:10AM  
07:10AM  
07:04AM  
Feb-11-21 04:01PM  
Feb-01-21 11:30AM  
10:34AM  
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; a collaboration, license, and option agreement with Visterra, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with Generation Bio., as well as GlaxoSmithKline Intellectual Property Development Limited, GlaxoSmithKline Biologicals SA., and Alnylam Pharmaceuticals, Inc. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was founded in 2016 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Virgin HerbertEVP, Research & CSOJul 27Option Exercise1.531,3752,104101,075Jul 28 07:34 PM
Virgin HerbertEVP, Research & CSOJul 27Sale36.721,37550,49099,700Jul 28 07:34 PM
Pang PhillipChief Medical OfficerJul 21Option Exercise1.574,6307,292113,907Jul 23 05:00 PM
Pang PhillipChief Medical OfficerJul 21Sale37.444,630173,347109,277Jul 23 05:00 PM
SATO VICKI LDirectorJul 19Sale37.2015,174564,5091,626,962Jul 20 08:51 PM
MORE ROBERT JDirectorJul 15Sale35.5611,670415,01246,029Jul 19 08:20 PM
Virgin HerbertEVP, Research & CSOJul 13Option Exercise1.531,3752,104101,075Jul 14 05:46 PM
Virgin HerbertEVP, Research & CSOJul 13Sale36.721,37550,49099,700Jul 14 05:46 PM
Pang PhillipChief Medical OfficerJul 07Option Exercise5.175,00025,875114,277Jul 08 05:32 PM
Pang PhillipChief Medical OfficerJul 07Sale40.395,000201,931109,277Jul 08 05:32 PM
MORE ROBERT JDirectorJul 01Sale44.9211,670524,27057,699Jul 06 05:01 PM
Rice Steven J.Chief Administrative OfficerJun 25Option Exercise12.7633820,003Jun 29 05:12 PM
Rice Steven J.Chief Administrative OfficerJun 25Sale50.00315020,000Jun 29 05:12 PM
Virgin HerbertEVP, Research & CSOJun 23Option Exercise1.538,00012,24099,700Jun 24 04:36 PM
SATO VICKI LDirectorJun 21Sale46.1715,174700,5151,642,136Jun 22 07:57 PM
MORE ROBERT JDirectorJun 17Sale43.9511,670512,84069,369Jun 21 05:08 PM
Pang PhillipChief Medical OfficerJun 16Option Exercise5.175,00025,875114,277Jun 17 05:04 PM
Pang PhillipChief Medical OfficerJun 16Sale43.675,000218,346109,277Jun 17 05:04 PM
Virgin HerbertEVP, Research & CSOJun 15Option Exercise1.531,3752,10493,075Jun 17 05:03 PM
Virgin HerbertEVP, Research & CSOJun 15Sale45.291,37562,27491,700Jun 17 05:03 PM
MORE ROBERT JDirectorJun 03Sale44.5611,670520,03381,039Jun 07 08:36 PM
Pang PhillipChief Medical OfficerJun 02Option Exercise0.8510,0008,550119,277Jun 03 07:30 PM
Pang PhillipChief Medical OfficerJun 02Sale41.4910,000414,874109,277Jun 03 07:30 PM
Virgin HerbertEVP, Research & CSOJun 01Option Exercise1.531,3752,10493,075Jun 02 05:38 PM
Virgin HerbertEVP, Research & CSOJun 01Sale42.511,37558,45191,700Jun 02 05:38 PM
MORE ROBERT JDirectorMay 20Sale44.5011,670519,35189,335May 24 09:25 PM
SATO VICKI LDirectorMay 19Sale43.8015,174664,6011,653,936May 20 07:53 PM
Virgin HerbertEVP, Research & CSOMay 18Option Exercise1.531,3752,10493,075May 19 04:39 PM
Virgin HerbertEVP, Research & CSOMay 18Sale45.031,37561,91691,700May 19 04:39 PM
Virgin HerbertEVP, Research & CSOMay 04Option Exercise1.531,3752,10493,075May 05 07:36 PM
Virgin HerbertEVP, Research & CSOMay 04Sale46.031,37563,29191,700May 05 07:36 PM
Virgin HerbertEVP, Research & CSOApr 27Option Exercise1.537,90012,08799,600Apr 28 04:41 PM
Virgin HerbertEVP, Research & CSOApr 27Sale49.507,900391,07791,700Apr 28 04:41 PM
Virgin HerbertEVP, Research & CSOApr 19Option Exercise1.532,3403,58094,040Apr 20 06:18 PM
Virgin HerbertEVP, Research & CSOApr 19Sale48.002,340112,32091,700Apr 20 06:18 PM
Virgin HerbertEVP, Research & CSOApr 16Option Exercise1.533,5005,35591,700Apr 19 08:00 PM
Virgin HerbertEVP, Research & CSOApr 13Option Exercise1.535,5608,50793,760Apr 15 05:36 PM
Virgin HerbertEVP, Research & CSOApr 13Sale43.575,560242,24488,200Apr 15 05:36 PM
Virgin HerbertEVP, Research & CSOApr 09Option Exercise1.5314,00021,42088,200Apr 12 08:23 PM
Parrish JayChief Business OfficerApr 01Option Exercise1.526,94410,52016,204Apr 05 05:00 PM
Parrish JayChief Business OfficerApr 01Sale51.406,944356,9569,260Apr 05 05:00 PM
Virgin HerbertEVP, Research & CSOMar 23Option Exercise1.537,90012,08782,100Mar 25 05:26 PM
Virgin HerbertEVP, Research & CSOMar 23Sale53.607,900423,40874,200Mar 25 05:26 PM
Virgin HerbertEVP, Research & CSOMar 10Option Exercise1.532,3403,58076,540Mar 12 04:28 PM
Virgin HerbertEVP, Research & CSOMar 10Sale48.002,340112,32074,200Mar 12 04:28 PM
Virgin HerbertEVP, Research & CSOMar 09Option Exercise1.535,5608,50779,760Mar 10 04:58 PM
Virgin HerbertEVP, Research & CSOMar 09Sale44.805,560249,08674,200Mar 10 04:58 PM
Parrish JayChief Business OfficerMar 01Option Exercise1.516,94410,52016,204Mar 03 04:35 PM
Parrish JayChief Business OfficerMar 01Sale63.446,944440,5319,260Mar 03 04:35 PM
Virgin HerbertEVP, Research & CSOFeb 23Option Exercise1.5318,90028,91782,100Feb 25 04:25 PM
Virgin HerbertEVP, Research & CSOFeb 23Sale63.747,900503,57774,200Feb 25 04:25 PM
Pang PhillipChief Medical OfficerFeb 16Option Exercise0.8510,0008,55077,277Feb 18 05:01 PM
Pang PhillipChief Medical OfficerFeb 12Option Exercise0.8510,0008,55067,277Feb 17 05:25 PM
Virgin HerbertEVP, Research & CSOFeb 09Option Exercise1.537,90012,08741,100Feb 10 04:33 PM
Virgin HerbertEVP, Research & CSOFeb 09Sale71.167,900562,16133,200Feb 10 04:33 PM
Parrish JayChief Business OfficerFeb 01Option Exercise1.556,94410,729229,166Feb 02 06:00 PM
Parrish JayChief Business OfficerFeb 01Sale69.916,944485,424222,222Feb 02 06:00 PM
Virgin HerbertEVP, Research & CSOJan 26Option Exercise1.5331,30047,88964,500Jan 27 06:39 PM
Virgin HerbertEVP, Research & CSOJan 26Sale48.1731,3001,507,80633,200Jan 27 06:39 PM
Virgin HerbertEVP, Research & CSOJan 15Option Exercise1.5310,53016,11143,730Jan 19 05:00 PM
Virgin HerbertEVP, Research & CSOJan 15Sale38.0010,530400,14033,200Jan 19 05:00 PM
Virgin HerbertEVP, Research & CSOJan 12Option Exercise1.533,8055,82237,005Jan 13 06:38 PM
Virgin HerbertEVP, Research & CSOJan 12Sale29.363,805111,69633,200Jan 13 06:38 PM
Parrish JayChief Business OfficerJan 04Option Exercise1.496,94510,313229,167Jan 05 04:40 PM
Parrish JayChief Business OfficerJan 04Sale26.326,945182,795222,222Jan 05 04:40 PM
Virgin HerbertEVP, Research & CSODec 24Option Exercise1.539,50014,53533,200Dec 28 06:39 PM
Virgin HerbertEVP, Research & CSODec 22Option Exercise1.533,8055,82227,505Dec 23 06:06 PM
Virgin HerbertEVP, Research & CSODec 22Sale31.193,805118,68323,700Dec 23 06:06 PM
Virgin HerbertEVP, Research & CSODec 08Option Exercise1.533,8055,82227,505Dec 10 05:00 PM
Virgin HerbertEVP, Research & CSODec 08Sale31.273,805118,96623,700Dec 10 05:00 PM
Parrish JayChief Business OfficerDec 01Option Exercise1.516,94510,522229,167Dec 02 05:48 PM
Parrish JayChief Business OfficerDec 01Sale31.536,945218,968222,222Dec 02 05:48 PM
Virgin HerbertEVP, Research & CSONov 27Option Exercise1.532,9304,48326,630Dec 01 07:02 PM
Pang PhillipChief Medical OfficerNov 27Option Exercise0.857,5006,41257,277Dec 01 07:03 PM
Virgin HerbertEVP, Research & CSONov 27Sale30.002,93087,90023,700Dec 01 07:02 PM
Virgin HerbertEVP, Research & CSONov 24Option Exercise1.532,3403,58026,040Nov 25 05:00 PM
Virgin HerbertEVP, Research & CSONov 24Sale27.292,34063,84823,700Nov 25 05:00 PM
Pang PhillipChief Medical OfficerNov 12Option Exercise0.8520,00017,10049,777Nov 16 05:00 PM
Virgin HerbertEVP, Research & CSONov 10Option Exercise1.532,3403,58026,040Nov 12 05:00 PM
Virgin HerbertEVP, Research & CSONov 10Sale26.262,34061,44823,700Nov 12 05:00 PM
Pang PhillipChief Medical OfficerNov 04Option Exercise1.535,0007,65034,777Nov 05 05:00 PM
Parrish JayChief Business OfficerNov 02Option Exercise1.526,94410,520229,166Nov 03 05:00 PM
Parrish JayChief Business OfficerNov 02Sale31.276,944217,153222,222Nov 03 05:00 PM
Virgin HerbertEVP, Research & CSOOct 27Option Exercise1.533,8055,82227,505Oct 28 07:43 PM
Virgin HerbertEVP, Research & CSOOct 27Sale35.043,805133,33523,700Oct 28 07:43 PM
Pang PhillipChief Medical OfficerOct 21Option Exercise2.2112,50027,66742,277Oct 22 06:15 PM
Pang PhillipChief Medical OfficerOct 21Sale35.4912,500443,60829,777Oct 22 06:15 PM
Pang PhillipChief Medical OfficerOct 21Sale31.445,000157,20929,777Nov 05 05:00 PM
Virgin HerbertEVP, Research & CSOOct 13Option Exercise1.535,5608,50729,260Oct 14 06:33 PM
Virgin HerbertEVP, Research & CSOOct 13Sale43.035,560239,23623,700Oct 14 06:33 PM
Pang PhillipChief Medical OfficerOct 07Option Exercise1.5412,50019,22942,277Oct 08 05:00 PM
Pang PhillipChief Medical OfficerOct 07Sale41.7412,500521,79529,777Oct 08 05:00 PM
Parrish JayChief Business OfficerOct 01Option Exercise1.516,94510,522229,167Oct 02 05:19 PM
Parrish JayChief Business OfficerOct 01Sale34.756,945241,342222,222Oct 02 05:19 PM
Virgin HerbertEVP, Research & CSOSep 29Option Exercise1.533,5105,37027,210Oct 01 05:00 PM
Virgin HerbertEVP, Research & CSOSep 29Sale38.003,510133,38023,700Oct 01 05:00 PM
Virgin HerbertEVP, Research & CSOSep 24Option Exercise1.533,7005,66123,700Sep 28 05:00 PM
Virgin HerbertEVP, Research & CSOSep 22Option Exercise1.533,8055,82223,805Sep 23 05:00 PM
Virgin HerbertEVP, Research & CSOSep 22Sale31.713,805120,63820,000Sep 23 05:00 PM
Pang PhillipChief Medical OfficerSep 16Option Exercise2.2412,50028,00142,277Sep 18 05:00 PM